Cell Medica Archives

News and Trends 1 May 2019

Next-Generation CAR-T Therapy Shows Promise in Child’s Neuroblastoma

Cell Medica’s next-generation CAR-T cell therapy has resulted in ‘extensive tumor regression’ in a child with high-risk neuroblastoma, one of the deadliest types of childhood cancer. Only available to cancer patients for the last couple of years, CAR-T cell therapy has had impressive results in treating patients for whom other available options do […]

May 1, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Feb 2019

UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic

The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […]

February 27, 2019 - 3 minutesmins - By Jonathan Smith

Best in Biotech 20 Feb 2018

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on the brain, we thought it would be a good time to do a roundup of Europe’s best-funded private biotechs. With over €400M raised to date, […]

February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt

Cell Medica Catapult Therapy TCR Acquisition

News and Trends 21 Jun 2017

British Biotech Tops up its Cancer Pipeline with New TCR Therapy

Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […]

June 21, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 16 Mar 2017

UK Immunotherapy Biotech raises Massive Funding in Series C

The UK biotech Cell Medica picked up a massive €69M (£60M) in its recent Series C funding round to advance its cancer immunotherapy programs. Cell Medica is a clinical stage company developing cell-based therapies to treat cancer. With the aim of advancing the clinical development of its immunotherapies, the company was able to raise an impressive […]

March 16, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 21 Feb 2017

New Immunotherapy Candidate receives FDA Fast Track Designation

Cell Medica’s Orphan Drug CMD-003 has received fast track designation by the FDA to advance immunotherapy of patients with Epstein Bar Virus (EBV)-associated malignancies. The FDA’s fast track designation has been designed to facilitate and accelerate the development of drugs which fill a major unmet medical need. It has now been granted to Cell Medica’s lead EBV immunotherapy […]

February 21, 2017 - 3 minutesmins - By Melanie De Almeida

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us